Myriad Genetics, Inc.
MYGN today announced that Noridian, the Medicare Administrator for
Utah, has notified Myriad of its intent to add the Company's prostate
prognostic test, Prolaris®, to its next draft Non-Covered Service LCD (local
coverage determination). Noridian will solicit public and provider comment on
the Prolaris test before making a final decision.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in